We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Three former Genentech employees were indicted by a federal grand jury for allegedly stealing trade secrets from the San Francisco-based Roche subsidiary, which is pursuing litigation of its own against the ex-staffers. Read More
Spring Pharmaceuticals sued incarcerated ex-pharma CEO Martin Shkreli and his former biopharmaceutical company Retrophin for blocking generics of its kidney stone drug Thiola. Read More
An outside consultant hired by Insys found serious compliance issues with the speakers programs, such as an absence of safety content and no clear disclosure of Insys sponsorship. Read More
The Attorney General said the company distributed the copayment coupons to consumers throughout New York “without clearly and conspicuously disclosing” the terms and conditions. Read More
The latest opioid report from the office of Sen. Claire McCaskill (D-Mo.) delves into Insys Therapeutics’ sales policies for Subsys and concludes that the drugmaker used unethical methods to increase sales of its fentanyl product. Read More
Insurance giant Humana sued more than two dozen generic drugmakers in a federal court on Aug. 3 alleging they conspired to inflate prices for commonly used drugs. Read More
“The opioid crisis these pills have fueled is a failure of policy and oversight by the government and a failure … on the part of many pharmaceutical companies and distributors,” McCaskill said. Read More
In her third report on opioid abuse in the U.S., Sen. Claire McCaskill (D-Mo.) recommends giving the DEA more authority to penalize pharmaceutical distributors for failing to meet reporting obligations, and cites widely varying reporting numbers of big distributors as a sign of waning DEA enforcement. Read More